Proteomic analyses identify HK1 and ATP5A to be overexpressed in distant metastases of lung adenocarcinomas compared to matched primary tumors
暂无分享,去创建一个
J. Kirfel | T. Gemoll | H. Pasternack | C. Kümpers | Thorben Sauer | Sofie Hinrichs | P. Lazar‐Karsten | Mirjam Polzer | Sabine Bohnet | Sven Perner | Franz F Dressler
[1] Kellen L. Olszewski,et al. Spatial mapping of mitochondrial networks and bioenergetics in lung cancer , 2023, Nature.
[2] Z. Szallasi,et al. Proteomic analysis of brain metastatic lung adenocarcinoma reveals intertumoral heterogeneity and specific alterations associated with the timing of brain metastases , 2022, ESMO open.
[3] S. Perner,et al. Normics: Proteomic Normalization by Variance and Data-Inherent Correlation Structure , 2022, Molecular & cellular proteomics : MCP.
[4] S. Perner,et al. Systematic evaluation and optimization of protein extraction parameters in diagnostic FFPE specimens , 2022, Clinical Proteomics.
[5] A. Schulz,et al. Protein Expression of AEBP1, MCM4, and FABP4 Differentiate Osteogenic, Adipogenic, and Mesenchymal Stromal Stem Cells , 2022, International journal of molecular sciences.
[6] M. Marz,et al. A genome‐wide CRISPR activation screen reveals Hexokinase 1 as a critical factor in promoting resistance to multi‐kinase inhibitors in hepatocellular carcinoma cells , 2022, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[7] A. Brazma,et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences , 2021, Nucleic Acids Res..
[8] E. Brzeziańska-Lasota,et al. Proteomic biomarkers of non-small cell lung cancer patients. , 2021, Advances in respiratory medicine.
[9] F. Klauschen,et al. Comprehensive micro-scaled proteome and phosphoproteome characterization of archived retrospective cancer repositories , 2021, Nature Communications.
[10] Dian Yang,et al. Altered Mitochondria Functionality Defines a Metastatic Cell State in Lung Cancer and Creates an Exploitable Vulnerability , 2020, Cancer Research.
[11] Paul D Piehowski,et al. A review of imputation strategies for isobaric labeling-based shotgun proteomics. , 2020, Journal of proteome research.
[12] I. Jonassen,et al. Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression , 2020, Cell.
[13] Junming Xu,et al. Integrative Proteomic Characterization of Human Lung Adenocarcinoma , 2020, Cell.
[14] Jeffrey R. Whiteaker,et al. Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma , 2020, Cell.
[15] W. Klepetko,et al. Current therapy of KRAS-mutant lung cancer , 2020, Cancer and Metastasis Reviews.
[16] H. Kwon,et al. Proteomic analysis enables distinction of early‐ versus advanced‐stage lung adenocarcinomas , 2020, Clinical and translational medicine.
[17] R. Gasparri,et al. Clinical Application of Mass Spectrometry‐Based Proteomics in Lung Cancer Early Diagnosis , 2020, Proteomics. Clinical applications.
[18] J. Nikliński,et al. Identification of protein changes in the blood plasma of lung cancer patients subjected to chemotherapy using a 2D-DIGE approach , 2019, PloS one.
[19] Damian Szklarczyk,et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..
[20] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[21] Gautam Sethi,et al. Sorcin a Potential Molecular Target for Cancer Therapy , 2018, Translational oncology.
[22] T. Graeber,et al. A precision therapeutic strategy for hexokinase 1-null, hexokinase 2-positive cancers , 2018, Cancer & Metabolism.
[23] P. Maher,et al. The mitochondrial ATP synthase is a shared drug target for aging and dementia , 2018, Aging cell.
[24] Steven J. M. Jones,et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2017, Cell.
[25] Semon Wu,et al. Haptoglobin is a serological biomarker for adenocarcinoma lung cancer by using the ProteomeLab PF2D combined with mass spectrometry. , 2016, American journal of cancer research.
[26] Yu-Sun Chang,et al. Identification and Characterization of Potential Biomarkers by Quantitative Tissue Proteomics of Primary Lung Adenocarcinoma* , 2016, Molecular & Cellular Proteomics.
[27] Richard D. Smith,et al. The clinical impact of recent advances in LC-MS for cancer biomarker discovery and verification , 2016, Expert review of proteomics.
[28] G. von Heijne,et al. Tissue-based map of the human proteome , 2015, Science.
[29] Yan Li,et al. Aberrant Mucin5B expression in lung adenocarcinomas detected by iTRAQ labeling quantitative proteomics and immunohistochemistry , 2013, Clinical Proteomics.
[30] Abhishek K. Jha,et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. , 2013, Cancer cell.
[31] T. Berkelman,et al. A Defined Methodology for Reliable Quantification of Western Blot Data , 2013, Molecular Biotechnology.
[32] K. J. Thomas,et al. The role of mitochondria in the development and progression of lung cancer , 2013, Computational and structural biotechnology journal.
[33] Francesca Pentimalli,et al. Mass spectrometry-based proteomics: the road to lung cancer biomarker discovery. , 2013, Mass spectrometry reviews.
[34] H. Juan,et al. Ectopic ATP synthase blockade suppresses lung adenocarcinoma growth by activating the unfolded protein response. , 2012, Cancer research.
[35] Sébastien Couraud,et al. Lung cancer in never smokers--a review. , 2012, European journal of cancer.
[36] Jiao-Yang Li,et al. Identification of Candidate Biomarkers for Early Detection of Human Lung Squamous Cell Cancer by Quantitative Proteomics* , 2012, Molecular & Cellular Proteomics.
[37] Yie Yang,et al. Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer , 2010, Medical oncology.
[38] P. He,et al. Expression profile of RhoGDI2 in lung cancers and role of RhoGDI2 in lung cancer metastasis. , 2010, Oncology reports.
[39] M. P. Cadena,et al. On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion. , 2010, Journal of proteomics.
[40] H. Tojo,et al. Proteomic analysis of laser-microdissected paraffin-embedded tissues: (1) Stage-related protein candidates upon non-metastatic lung adenocarcinoma. , 2010, Journal of proteomics.
[41] H. Tojo,et al. Proteomic analysis of laser-microdissected paraffin-embedded tissues: (2) MRM assay for stage-related proteins upon non-metastatic lung adenocarcinoma. , 2010, Journal of proteomics.
[42] M. Roehrl,et al. Tissue proteomics reveals differential and compartment-specific expression of the homologs transgelin and transgelin-2 in lung adenocarcinoma and its stroma. , 2009, Journal of proteome research.
[43] L. Gaspar,et al. National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. , 2007, Lung cancer.
[44] Haesun Park,et al. Sparse non-negative matrix factorizations via alternating non-negativity-constrained least squares for microarray data analysis , 2007, Bioinform..
[45] Ning Liu,et al. Overexpression of sorcin in multidrug resistant human leukemia cells and its role in regulating cell apoptosis. , 2006, Biochemical and biophysical research communications.
[46] Hoguen Kim,et al. Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of nonsmall cell lung carcinoma , 2004, Proteomics.
[47] C. Moskaluk,et al. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. , 2002, Cancer research.
[48] B. Silvestrini,et al. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. , 1981, Cancer research.
[49] Cathy H. Wu,et al. UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..